Vaxxinova acquires Epitopix
February 22, 2018
Vaxxinova acquires Epitopix
Vaxxinova, an EW-group company with core business focusing on animal health, has concluded an agreement to acquire 100% of the shares in Epitopix, a US based animal health company specialized in poultry and livestock biologicals and founder of SRP® technology. The transaction will be concluded by February 28, 2018.
Epitopix is a part of the Willmar Poultry group of companies, both of which are based in Willmar, Minnesota, USA. Epitopix was established in 2002 and has developed various breakthrough technologies for livestock and poultry vaccines.
Dr Jim Sandstrom –Managing Director of Epitopix about the acquisition:
“The acquisition by Vaxxinova provides Epitopix a chance to accelerate our growth in the poultry and livestock vaccine markets,” according to Dr. Jim Sandstrom, Managing Director of Epitopix. “Since the founding of Epitopix, we have been under the protective wing of our parent, Willmar Poultry Company. Now we’ll have the ability to fly, with the experience of an international team to guide us and new resources under our wings.”
Victor van Solinge – CEO Vaxxinova about the acquisition:
“This transaction is very good news for the global veterinary industry and especially our customers, business partners and employees. This acquisition makes SRP technology available across the world” says Victor van Solinge, CEO Vaxxinova. “Epitopix’ technology combined with Vaxxinova’s technology, resources and global presence allows us to develop new vaccines across many species globally for existing and new disease challenges. We see an excellent cultural, strategic and operational fit between the companies. The 2 companies have a similar culture, as both are part of a family-owned group originating from animal breeding and genetics. The Epitopix management team brings a wealth of experience and a proven technology platform, and we are looking forward to mutually develop and discover new synergies. This transaction is also great news for Willmar, Minnesota as Willmar will be the nucleus for further growth of Vaxxinova’s Animal Health business in the United States. We anticipate extending our organization by recruiting Animal Health professionals as well as investing in our technical capabilities in Willmar.”
Epitopix is an animal health company owned by the Willmar Poultry group of companies, in Willmar, Minnesota, USA. Epitopix management and board has deep industry experience in animal production and within the veterinary biological sector and has numerous patents globally on SRP® technology.
Vaxxinova is a global animal health player specialized in disease and performance management of production animals. The company operates in more than 50 countries and has its headquarters in Nijmegen, The Netherlands. Vaxxinova has R&D, production and diagnostic facilities in Brazil, Germany, Italy, Norway, Japan, Jordan, the Netherlands and now USA. Vaxxinova is 100% owned by the EW Group.
About EW Group
EW Group, with headquarters in Visbek, Germany, is a 100% family-owned holding company and is specialized in animal genetics, animal nutrition and animal health.